Tumefactive rebound of Multiple Sclerosis following cessation of Fingolimod Sharfaraz Salam, Daniel Dunbar, Tim Lavin, Adrian Pace, Tatiana Mihalova.

Slides:

Advertisements

Similar presentations

Diffuse Encephalitis Diagnosed on PET/CT Acquired in a Patient in Status Epilepticus with Negative MRI J Cain 1,2, J Hill 2, C Coutinho 2, S Mathur 2 1.

Advertisements

FREEDOMS II TRIAL.

An Analysis of Monthly Surveillance 3T MRI in MS patients switched from long term natalizumab to teriflunomide in a controlled, prospective study K. Edwards,

Multiple Sclerosis Rohith M. Reddy. Multiple sclerosis (MS) involves an immune-mediated process in which an abnormal response of the body’s immune system.

Sagittal FLAIR images - Stable nonenhancing hyperintensities within the pericallosal white matter and bilateral centrum semiovale, consistent with known.

Int J MS Care 7: , 2005/2006. Jan 9 & 10, Clinical Stabilization of a MS Patient after Tonsillectomy presented by Michael C. Levin, MD Department.

A 30-year male with cognitive decline and unsteady gait Teaching NeuroImages Neurology Resident and Fellow Section © 2013 American Academy of Neurology.

POSTER TITLE: CLINICAL AND RADIOLOGICAL PROFILE, TREATMENT AND OUTCOME OF PEDIATRIC ACQUIRED DEMYELINATING DISORDERS OF CENTRAL NERVOUS SYSTEM PRESENTER.

Carrie M. Hersh, D.O., Robert Fox, M.D.

Four Known Types of MS Clinically isolated syndrome (CIS)

Neurology Resident and Fellow Section

A 26-y.o. woman with RRMS and eruption of plaques.

Nat. Rev. Neurol. doi: /nrneurol

Copyright © 2005 American Medical Association. All rights reserved.

Propensity Score Adjustment for Comparative Efficacy Studies of Disease Modifying Agents in Multiple Sclerosis Carrie M. Hersh, DO,1 Claire Hara-Cleaver,

Copyright © 2015 by the American Osteopathic Association.

Figure 1 An example of individual prediction of response to interferon β-1a and natalizumab in moderately advanced, active multiple sclerosis. Six treatment.

Figure 2. MRI features of patients with MS who had antibodies to myelin oligodendrocyte glycoprotein MRI features of patients with MS who had antibodies.

Figure 1 Initial brain imaging (A–C) patient 1; (D–F) patient 2; (G–I) patient 3; (J–L) patient 4; and (M) patient 2. Initial brain imaging (A–C) patient.

Reversible posterior leukoencephalopathy syndrome and silent cerebral infarcts are associated with severe acute chest syndrome in children with sickle.

Nat. Rev. Neurol. doi: /nrneurol

Stephen L. Hauser, Jorge R. Oksenberg Neuron

Figure 3 Archetypal MS clinical course depicted over 20 years

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Figure 3 Example of venous narrowing

Figure 3 MRI findings in opportunistic infections of the CNS

Figure 2 Clinical course and response to therapy in 6 Australian patients with HMGCR antibodies The clinical course, creatine kinase (CK) levels, Medical.

Figure Nuclear Nrf2 expression after fumarate therapy A new left occipital fluid-attenuated inversion recovery hyperintense (A), T1 hypointense (B), and.

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 2 Exemplary MRI of a patient with contrast enhancement on postcontrast FLAIR MRI of a 54-year-old patient with viral meningitis caused by varicella-zoster.

Figure 2 7T MRI can differentiate between early PML and MS lesions Two different patterns of brain lesions were observed using 7T MRI: ring-enhancing lesions.

Chapter 16 Neurologic Dysfunction and Kidney Disease

Figure 2 Forest plots for subgroup analyses

In 507 follow-up images, only 1

Figure 1 White matter lesion central vein visibility in MS and absence in small vessel disease (SVD)‏ White matter lesion central vein visibility in MS.

Figure 2 Example of venous narrowing

Figure 1 MRI of inflammatory myelitis before and after treatment

Figure 1 Illustration of white matter– and lesion-associated regions of interest (ROIs)‏ Illustration of white matter– and lesion-associated regions of.

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Cerebral and spinal MRI (A) Restricted diffusion of both optic nerves (arrows) on diffusion-weighted and apparent diffusion coefficient imaging.

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

Longitudinal Characterization of Cortical Lesion Development and Evolution in Multiple Sclerosis with 7.0-T MRI In patients with multiple sclerosis, 7.0-T.

Figure 1 Evolution of MRI findings during interleukin (IL)–7 therapy

Figure 1 Imaging of disease onset and treatment response Repeat MRI scans including fluid-attenuated inversion recovery (FLAIR) (A) and T2 fast field echo.

Figure 1 Radiologic features of patients with white matter syndromes in association with NMDA receptor antibodies Radiologic features of patients with.

Figure 1 MRI findings over time

Figure Brain MRI findings before and during appearance of lymphoproliferative disorder and pathology findings of cerebellar lesion Brain MRI findings before.

Figure 4 Four representative disease-course archetypes

Figure Spinal cord imaging (A, B) Sagittal and axial T2-weighted cervical spine MRI demonstrating hyperintensities in the central gray matter of patient.

Figure 1 Detailed overview of treatment course and paraclinical findings Maximum intensity projection maps of supratentorial inversion recovery images.

MR images of patient 2 (with juvenile-onset DRPLA).

Figure 1 MRIs (case 1)‏ MRIs (case 1) An enlarging T2 lesion in the cerebral white matter near the angular gyrus and a new lesion in the left middle cerebellar.

Figure 2 MRIs (cases 2 and 3)‏

Figure 1 Imaging and histopathologic characteristics of patients with CNS-FHL Imaging and histopathologic characteristics of patients with CNS-FHL FLAIR.

Figure 2 Characteristic MRI features of adult leukodystrophies

Figure Rapid progression of lesions after natalizumab treatment(A) MRI from February Rapid progression of lesions after natalizumab treatment(A)

Figure A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia A 57-year-old man with relapsing-remitting MS (RRMS) and new-onset ataxia.

Figure 4 Patient 3 MRI evolution over time

Figure 15a. PMLprogressive multifocal leukoencephalopathy in a 65-year-old woman with multiple medical problems, no known immunosuppressive disease, and.

Figure 2 Clinical data and variation of sNfL levels of patients 4–6 with ATZ-treated MS Clinical data and variation of sNfL levels of patients 4–6 with.

Axial MRI of a 46 year old man with secondary progressive MS showing a large left sided periventricular lesion which is hyperintense with (A) T2 weighted.

Figure 3 Patient 2 MRI evolution over time before relapse

Sequential axial T1-weighted noncontrast mag-netic resonance images through the posterior fossa of a 52-year-old male with history of multiple sclerosis.

Images from the case of an 8-year-old female patient with complex I mitochondrial disease, which was diagnosed when the patient was older than 3 years.

Axial magnetic resonance imaging (MRI) of a 30 year old man with relapsing remitting multiple sclerosis (MS) showing multiple periventricular lesions:

Figure 1 MRIs MRIs (A and B) Axial FLAIR images of the brain demonstrate multifocal parenchymal lesions including the right hippocampus, right midbrain,

Chronic CNS-IRIS without coinfection.

Brain MRI performed with 1

Marked progression of PML documented by serial MR studies

Presentation transcript:

Tumefactive rebound of Multiple Sclerosis following cessation of Fingolimod Sharfaraz Salam, Daniel Dunbar, Tim Lavin, Adrian Pace, Tatiana Mihalova Greater Manchester Neurosciences Centre, Salford Royal NHS Foundation Trust Background Fingolimod is an oral sphingosine-1-phosphate receptor modulator approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Recent reports have highlighted the possible risk of rebound disease activity after withdrawal of fingolimod. We describe a patient who developed severe tumefactive lesions on discontinuing fingolimod treatment. Patient History A 32 year old female with RRMS escalated treatment from interferon beta to fingolimod due to ongoing relapses. We aimed to switch treatment from fingolimod to alemtuzumab. She discontinued fingolimod in May 2015. However by July 2015 the side effects related to fingolimod resolved. She started a modified diet and low-dose naltrexone therapy. She now declined treatment with alemtuzumab, anticipating further side effects. However she consented to repeat MRI in 2 months and further discussion to reconsider alemtuzumab. . Figure.2. T2 axial images performed in April 2015 (a) shows a moderate number of periventricular white matter demyelinating lesions, and August 2015 (b) show multiple large active tumefactive lesions in the periventricular white matter and subcortical white matter. FLAIR sagittal images performed in April 2015 (c) and August 2015 (d), illustrate an increase lesion load in the periventricular and subcortical white matter in August 2015. Relapse with Fingolimod There have been reports of severe rebounds have rarely been reported after stopping fingolimod. Of such cases tumefactive lesions are more infrequently described. Immunosuppression with steroids has been previously used to treat such relapses after fingolimod cessation. De Masi et al report the use of Selective Immune Adsorption (SIA) as an alternative to treat a patient with a relapse following cessation of fingolimod therapy. They considered SIA as the rebound was refractory to intravenous steroid therapy. Our patient stabilized on steroids and intravenous alemtuzumab. Figure 1. a) T2 axial images b) FLAIR sagittal images showing extensive multifocal plaques, enhancing throughout both cerebral hemispheres and tumefactive disease in the right posterior capsular region extending into the brainstem and cerebellum. Learning points Although relapses following the cessation of fingolimod are uncommon it is important to be aware of the potential risk and advise patients to not stop treatment abruptly. It is important to carefully plan switching from oral therapy in multiple sclerosis avoiding prolonged periods without treatment. Rebound Progression In August 2015 she was admitted with an acute left hemisensory disturbance and tetraparesis. She also complained of dysphagia, weight loss, balance disturbance and worsening of memory. MRI images demonstrated severe rebound disease and numerous contrast enhancing tumefactive MS lesions (Figure.1 and 2). She was treated with intravenous steroids and alemtuzumab leading to partial neurological recovery after 6 months. References 1. Faissner S, Hoepner R, Lukas C, et al. Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Ther Adv Neurol Disord 2015;8:233-8 2. Havla JB, Pellkofer HL, Meinl I, et al. Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. Arch Neurol 2012;69:262-4 3. De Masi R, Accoto S, Orlando S, et al. Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption. BMC Neurol 2015;15:125